Topics, Trends & Updates

July 2025

View as web page

YouTube  Facebook  Linkedin  Instagram

New: Interim Guideline on the Use of Twice-Yearly Lenacapavir for HIV Prevention

In June 2025, the U.S. Food and Drug Administration approved lenacapavir (LEN), a long-acting HIV capsid inhibitor given subcutaneously every 6 months (along with an initial 2-day oral loading dose), for use as HIV pre-exposure prophylaxis (PrEP) for sexual exposures in adults and adolescents weighing ≥35 kg.


While the full PrEP for HIV prevention guideline is undergoing an update, lead authors Dr. Rona Vail and Aviva Cantor, with the Medical Care Criterial Committee, developed the Interim Guideline on the Use of Twice-Yearly Lenacapavir for HIV Prevention with the goal of providing interim guidance on the use of subcutaneous (SC) LEN as PrEP.


Contents:



Go to the full guideline

New Podcast: Viremic--Cases in HIV

Join hosts Christopher Hoffman, MD, and Eileen Scully, MD, HIV specialists at Johns Hopkins University, for a new biweekly podcast in which they’ll present and discuss challenging cases to explore quandaries in adult HIV care.


In each episode, Chris and Eileen will focus on one case, covering patient history, problem list, diagnoses, challenges, pertinent social issues at play, and treatment planning. They will also highlight key evidence, publications, and guidelines that informed the clinical decision-making. 


Case 1. Returning to Care – Is Biktarvy Always the Answer? This case focuses on a 48-year-old man with HIV for 12 years who presented 1 year after his last visit with a history of methamphetamine use, inconsistent engagement in care, and a new diabetes diagnosis. He reported no recent ART and no meth use for about 8 months and was motivated to resume ART. On returning to care, his viral load was 250,000 copies/mL, the CD4 count was 230 cells/mm3, creatinine levels were elevated, and genotype testing found a K103N mutation. Drs. Scully and Hoffmann evaluate the patient’s new ART options in light of his clinical viremia and comorbidities. Listen Now


Hot Topics


See all Hot Topics

Don't Miss

Updated: PEP to Prevent HIV Infection > Pediatric Care


Updates to this guideline include:


  • New recommendations, discussion, and references added throughout on bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) as a preferred single-tablet PEP regimen for children and adolescents who weigh ≥14 kg
  • Selecting and Initiating a 28-Day Course of PEP section: Detailed information on dosing of PEP for pediatric patients added in Table 4
  • Additional information on dosing of PEP for pediatric patients included in the Appendix: Dosing of nPEP Medications for Pediatric Patients Who Weigh <40 kg and/or Cannot Swallow Tablets

Conversations With CEI Podcast

Xylazine & Medetomidine & Nitazenes, Oh My! An Update on New York State’s Drug Supply: New York drug overdose deaths and death rates are on the decline, but with significant disparities, and the current, toxic drug supply is partially to blame. Harmful additives like fentanyl analogues, xylazine, and medetomidine, among others, have been found in cocaine, heroin, MDMA, and pressed into pills. Additives are undetectable by sight, taste, and smell, which increases the risk of overdose for people who use and may not be aware of what’s in their drug supply. This episode features Drs. Sharon Stancliff and Jennifer Love discussing additives commonly found in the New York State supply, including BTMPS, fentanyl analogues, medetomidine, nitazenes, and an update on xylazine. Listen Now

Upcoming Training, Education, and Events

CEI:

See all


General:

See all

Are You a Subscriber?



If this newsletter was forwarded to you, please subscribe now to make sure you receive the Clinical Guidelines Program Topics, Trends, and Updates newsletter every month and stay current with new and updated guidelines. We send 1 email per month and do not share our mailing list.

Comments? Questions? Suggestions?


Email us: aiguidelines@jhmi.edu. 

We'll get back to you as quickly as possible.


Note that we cannot answer questions about the care or treatment of specific patients and cannot provide clinical advice.